Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells 6,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $16.18, for a total value of $97,080.00. Following the completion of the sale, the general counsel now directly owns 105,386 shares in the company, valued at approximately $1,705,145.48. The trade was a 5.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Centessa Pharmaceuticals Trading Down 2.2 %

Shares of CNTA stock traded down $0.35 on Wednesday, hitting $15.91. The stock had a trading volume of 839,258 shares, compared to its average volume of 794,477. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a market capitalization of $2.10 billion, a P/E ratio of -10.40 and a beta of 1.53. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09. The company’s 50 day moving average price is $16.74 and its 200-day moving average price is $15.78.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $2,834,000. Wellington Management Group LLP purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $1,609,000. State Street Corp purchased a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $777,000. Ally Bridge Group NY LLC acquired a new position in Centessa Pharmaceuticals during the 3rd quarter worth $4,951,000. Finally, GSA Capital Partners LLP grew its stake in Centessa Pharmaceuticals by 66.1% during the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after purchasing an additional 37,275 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CNTA. TD Cowen began coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.